Literature DB >> 1477097

A novel alpha-type fibrinogenase from Agkistrodon rhodostoma snake venom.

T F Huang1, M C Chang, H C Peng, C M Teng.   

Abstract

By means of CM-Sephadex C-50 column chromatography, gel-filtration on sephadex G-75 and Sephacryl S-200 columns, a purified fibrinogenase, kistomin, was obtained from venom of Agkistrodon rhodostoma. It was a single peptide-chain with a molecular mass of about 21,800 Da containing about 202 amino-acid residues as revealed by amino acid analysis. Kistomin preferentially cleaved A alpha- and subsequently the gamma-chain of fibrinogen, leaving the B beta-chain unaffected. Its fibrinogenolytic activity was estimated to be 36.6 +/- 4.5 mg/min per mg protein and was inhibited by the pretreatment of EDTA, suggesting that it is a metalloproteinase. Its fibrinogenolytic activity in platelet-poor plasma is much less potent as compared to that in purified fibrinogen solution. It inhibited ristocetin-induced aggregation of human platelets in a dose-dependent manner in the presence of von Willebrand factor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1477097     DOI: 10.1016/0167-4838(92)90086-s

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

1.  Purification, molecular cloning and mechanism of action of graminelysin I, a snake-venom-derived metalloproteinase that induces apoptosis of human endothelial cells.

Authors:  W B Wu; S C Chang; M Y Liau; T F Huang
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

2.  Carbon monoxide releasing molecule-2 inhibition of snake venom thrombin-like activity: novel biochemical "brake"?

Authors:  Vance G Nielsen; Charles M Bazzell
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

Review 3.  Metalloproteases Affecting Blood Coagulation, Fibrinolysis and Platelet Aggregation from Snake Venoms: Definition and Nomenclature of Interaction Sites.

Authors:  R Manjunatha Kini; Cho Yeow Koh
Journal:  Toxins (Basel)       Date:  2016-09-29       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.